NIH, Blood and Marrow Transplant Clinical Trials Network, Krishnan (Co-I)
NIH/NCI/RO1, Characterizing and Targeting the Novel IL-15-AKT-XBP1s Pathways in NK Cells, Krishnan (Co-I)
NIH/NCI/RO1, Repurposing Leflunomide to Delay Progression of Smoldering Multiple Myeloma in African Americans, Rosen, Pichiorri and Rosenzweig
IMS, PNC-27: A Novel Effective Strategy for Targeting the Achilles’ Heel of Multiple Myeloma, Marcucci and Pichiorri
MMRF, Optimizing BCMA-Targeted Therapies, Pichiorri and Krishnan
The Leukemia & Lymphoma Society, Inc, Role of health insurance and Medicaid expansion in racial inequity in pattern of care and outcomes in Multiple Myeloma, Wong
MMRC, 2019 Primary objective is to determine the anti-myeloma activity of single agent daratumumab post ASCT, as assessed by progression-free survival at 1 year post ASCT, Krishnan
NIH/NCI/RO1, Reolysin-based combination therapy in relapsed multiple myeloma, Hofmeister and Pichiorri
NIH/NCI/RO1, Exploring the preclinical relevance of therapeutic radiolabeled daratumumab (anti- CD38) in combination with anti-CS1 CAR T cells as a novel combinatorial treatment for multiple myeloma, Rockne, Shively, Wang and Pichiorri
NIH/NCI, Improving Outcomes for Multiple Myeloma Patients through Novel Therapeutic Interventions, Pichiorri (Co-I)
The Leukemia & Lymphoma Society, Inc, Establishing Hematology Clinical Trial Hubs within the City of Hope Community and Affiliate Network, Siddiqi
NIH/NCI, Modeling based design of chimeric antigen receptors for Natural Killer cell-based Immunotherapy, Finely